IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy ...
Medtronic’s investment is contingent on Anteris completing a proposed $200 million public stock offering.
The Medtronic investment and the underwritten public offering of common stock position Anteris to continue to execute the global PARADIGM Trial and to continue investing in research that can transform ...
Medtronic will invest $90M in Anteris Technologies for DurAVR TAVR device development, contingent on a $200M IPO.
A federal judge has paused the merger of the only two companies developing a heart device made for high-risk patients suffering from ...
The global TAVR embolic protection market is experiencing steady growth, with revenue estimated to increase from approximately $124 million in 2023 to around $403 million by 2032. This growth, driven ...
Since it went on the market, the newer device has been the subject of several reports of hemolysis. This would seem ...
KUWAIT CITY, Jan 24: Kuwait’s Ministry of Health announced on Saturday the successful completion of the world’s first ...
Researchers have created a new noninvasive technique for performing a type of artery bypass that may change the future of ...
EW benefits from strong TAVR and TMTT momentum, but macro pressures and FX headwinds cloud the near-term outlook.
While many people fear a cancer diagnosis above all else, clinical data reveals that symptomatic aortic stenosis, a severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results